Compare ZDGE & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZDGE | RNXT |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | 55 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 38.8M |
| IPO Year | 2016 | 2021 |
| Metric | ZDGE | RNXT |
|---|---|---|
| Price | $2.99 | $0.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 75.8K | ★ 184.3K |
| Earning Date | 06-11-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.96% | N/A |
| EPS Growth | ★ 73.85 | 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,398,000.00 | $1,123,000.00 |
| Revenue This Year | $3.27 | $194.66 |
| Revenue Next Year | $5.78 | $279.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $2.21 | $0.70 |
| 52 Week High | $4.70 | $1.45 |
| Indicator | ZDGE | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 46.11 | 43.83 |
| Support Level | $2.88 | $0.84 |
| Resistance Level | $3.16 | $1.08 |
| Average True Range (ATR) | 0.12 | 0.04 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 8.83 | 28.18 |
Zedge Inc builds digital marketplaces and competitive games centered on content that people use for self-expression. Its products include the Zedge App, a freemium digital content marketplace offering mobile wallpapers, video wallpapers, ringtones, and notification sounds, along with pAInt, a generative AI wallpaper and ringtone maker, GuruShots, a skill-based photo challenge game, and Emojipedia, a trusted source for emoji information. The Zedge App is available on Google Play and the App Store. The company operates two segments: Zedge Marketplace and GuruShots, with the majority of revenue generated from the Zedge Marketplace.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.